Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292

Epidermal Growth Factor (EGF) Treatment on Multipotential Stromal Cells (MSCs). Possible Enhancement of Therapeutic Potential of MSC

(2010) Kenichi Tamama et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from German Centers in the TRUST Study

(2010) Claus-Peter Schneider et al.   Journal of Thoracic Oncology

Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers

(2010) KOH FURUGAKI et al.   Oncology Letters

Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases

(2009) T. A. Guise   GENES & DEVELOPMENT

1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression

(2009) Sadaoki Sakai et al.   JOURNAL OF BONE AND MINERAL METABOLISM

The EGFR network in bone biology and pathology

(2009) Marlon R. Schneider et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Predictors of Survival in Patients With Bone Metastasis of Lung Cancer

(2008) Hideshi Sugiura et al.   CLINICAL ORTHOPAEDICS AND RELATED RESEARCH

Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling

(2008) TacGhee Yi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity

(2008) Vera Hirsh et al.   Journal of Thoracic Oncology

Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib

(2008) Germano Zampa et al.   LUNG CANCER

Prolonged response to gefitinib in bone metastasis

(2008) Hiroaki Satoh et al.   MEDICAL ONCOLOGY